BioLineRX
BLRX
25 hedge funds and large institutions have $33.1M invested in BioLineRX in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 9 closing their positions.
0% less ownership
Funds ownership: 0.06% → 0.06% (-0%)
0% less capital invested
Capital invested by funds: $33.1M → $33.1M (-$19K)
11% less funds holding
Funds holding: 28 → 25 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$95.6K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.7K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$9.56K |
| 4 |
OC
Oppenheimer & Co
New York
|
+$9.03K |
| 5 |
VanEck Associates
New York
|
+$9.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$684K |
| 2 |
Renaissance Technologies
New York
|
-$195K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$106K |
| 4 |
Morgan Stanley
New York
|
-$103K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$78K |
BLRX Hedge Fund Activity: Q2 2018 in Review
25 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2018, worth a combined $33.1M — down 0.06% from $33.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BLRX and 7 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $95.6K. The largest seller was DZ Bank, exiting entirely with an estimated $684K sold.
- 25 institutional investors held BioLineRX (BLRX) as of Q2 2018, down from 28 in Q1 2018.
- Funds reported $33.1M of BioLineRX stock for Q2 2018, down 0.06% quarter-over-quarter.
- 7 funds opened new BioLineRX positions in Q2 2018 and 9 closed out, a net change of -2 holders.
- The largest BioLineRX buyer in Q2 2018 was Susquehanna International Group, an estimated $95.6K added.
- The largest BioLineRX seller in Q2 2018 was DZ Bank, an estimated $684K sold.
Based on aggregated 13F filings for Q2 2018.